AMLX

Amylyx Pharmaceuticals, Inc.

AMLX · CIK 0001658551 · Annual (10-K) · Last 4 years

Financial Trends

Revenue$0M
20222025
Net Income−$145M
20222025
Operating CF−$123M
20222025
Free Cash Flow−$123M
20222025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕
Revenue$0.0B$0.1B$0.4B$0.0B
Cost of Revenue$0.0B$0.0B$0.0B$0.0B
Gross Profit————
R&D Expense$0.1B$0.1B$0.1B$0.1B
SG&A Expense$0.1B$0.1B$0.2B$0.1B
Operating Income$-0.2B$-0.3B$0.0B$-0.2B
Net Income$-0.1B$-0.3B$0.0B$-0.2B
EPS (Basic)$-1.53$-4.43$0.73$-3.39
EPS (Diluted)$-1.53$-4.43$0.70$-3.39

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕
Total Assets$0.3B$0.2B$0.5B$0.4B
Current Assets$0.3B$0.2B$0.5B$0.4B
Cash & Equivalents$0.2B$0.1B$0.2B$0.1B
Total Liabilities$0.0B$0.0B$0.1B$0.1B
Current Liabilities$0.0B$0.0B$0.1B$0.0B
Stockholders' Equity$0.3B$0.2B$0.4B$0.3B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕
Operating Cash Flow$-0.1B$-0.2B$0.0B$-0.2B
Investing Cash Flow$0.0B$0.1B$0.1B$-0.2B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.3B$0.0B$0.0B$0.4B
← Companies